²é¿´: 2224  |  »Ø¸´: 21
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£

Àî½ðƽ

Í­³æ (ÕýʽдÊÖ)

[½»Á÷] ¡¾ÇóÖú¡¿ÖÆÒ©ÆóÒµµÄQ1aµ½Q10¶¼´ú±íʲô£¿

×î½ü¸ÕÈ¥Ò»¼ÒÖÆÒ©ÆóÒµ£¬²»ÖªµÀQ1aµ½Q10¶¼´ú±íʲô£¿
Óгæ×ÓÖªµÀµÄÂð£¿Ð»Ð»
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

cpugoodboy

ÖÁ×ðľ³æ (ÖøÃûдÊÖ)

ÕæµÄ×íÁ˲»»á³éÑÌ

¡ï
Àî½ðƽ(½ð±Ò+1):лл²ÎÓë

ICH£¨ÈËÓÃÒ©Æ·×¢²á¼¼ÊõÒªÇó¹ú¼ÊЭµ÷»á£©Ö¸µ¼Ô­Ôò
ÆäÖÐÖÊÁ¿£¨Quality£¬°üÀ¨Îȶ¨ÐÔ¡¢ÑéÖ¤¡¢ÔÓÖ¾¡¢¹æ¸ñµÈ£©£¬ÒÔ¡°Q¡±±íʾ£¬ÏÖÒÑÖÆ¶¨12¸öÎļþ

[ Last edited by cpugoodboy on 2009-7-24 at 07:24 ]
Ò»ÐÄÒ»Òâ´ýÀÏÆÅ£¬Å¼¶û¹à¹àË®¡­¡­
2Â¥2009-07-24 07:22:18
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

llb1978

½ð³æ (ÕýʽдÊÖ)

¡ï
Àî½ðƽ(½ð±Ò+1):лл²ÎÓë
http://www.ich.org/cache/compo/276-254-1.html

Stability

Q1A(R2) Stability Testing of New Drug Substances and Products


Q1B Stability Testing : Photostability Testing of New Drug Substances and Products


Q1C Stability Testing for New Dosage Forms


Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products


Q1E Evaluation of Stability Data


Q1F Stability Data Package for Registration Applications in Climatic Zones III and IV



Analytical Validation
Q2(R1) New title: Validation of Analytical Procedures: Text and Methodology
Previously: Text on Validation of Analytical Procedures
Q2A  
Validation of Analytical Procedures: Methodology (in Q2(R1)) Q2B  

Impurities
Q3A(R2) Impurities in New Drug Substances
Q3A(R)

Q3B(R2) Impurities in New Drug Products
Q3B(R)

Q3C(R4) Impurities: Guideline for Residual Solvents
Q3C

Impurities: Guideline for Residual Solvents (Maintenance)

PDE for Tetrahydrofuran (in Q3C(R3))
Q3C(M)  
PDE for N-Methylpyrrolidone (in Q3C(R3)) Q3C(M)  
Procedures are described here  

Pharmacopoeias
Q4 Pharmacopoeias
  
Q4A Pharmacopoeial Harmonisation
  
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions

  
Q4B
Annex 1 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
on Residue on Ignition/Sulphated Ash General Chapter

  
Q4B
Annex 2 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
on Test for Extractable Volume of Parenteral Preparations General Chapter

  
Q4B
Annex 3 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
on Test for Particulate Contamination: Sub-Visible Particles General Chapter

  
Q4B
Annex 4A Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
on Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests General Chapter

  
Q4B
Annex 4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
on Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms General Chapter
  
Q4B
Annex 4C Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
on Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter
  
Q4B
Annex 5 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
on Disintegration Test General Chapter
  
Q4B
Annex 6 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
on Uniformity of Dosage Units General Chapter   
Q4B
Annex 7 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
on Dissolution Test General Chapter   
Q4B
Annex 8 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
on Test for Sterility General Chapter   
Q4B
Annex 9 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
on Tablet Friability General Chapter   
Q4B
Annex 10 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
on Polyacramyde Gel Electrophoresis General Chapter   

Quality of Biotechnological Products
Q5A(R1) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin
Q5A

Q5B Quality of Biotechnological Products : Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products


Q5C Quality of Biotechnological Products : Stability Testing of Biotechnological/Biological Products


Q5D Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products


Q5E Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process



Specifications
Q6A Specifications : Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (including Decision Trees)


Q6B Specifications : Test Procedures and Acceptance Criteria for Biotechnological/Biological Products



Good Manufacturing Practice
Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7A  

Pharmaceutical Development
Q8(R1) Pharmaceutical Development  

Quality Risk Management
Q9 Quality Risk Management  

Pharmaceutical Quality System
Q10 Pharmaceutical Quality System  
   
Q8/9/10 Q&As Q8/Q9/Q10 - Questions & Answers document
ÑÏÓÚÂɼº,¿íÒÔ´ýÈË
3Â¥2009-07-24 07:23:59
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

the810

¡ï
Àî½ðƽ(½ð±Ò+1):лл²ÎÓë
Â¥ÉÏ˵µÄ¶Ô
4Â¥2009-07-24 07:24:30
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

reallove2935

½ûÑÔ (ÖøÃûдÊÖ)

¡ï
Àî½ðƽ(½ð±Ò+1):лл²ÎÓë
±¾ÌûÄÚÈݱ»ÆÁ±Î

5Â¥2009-07-24 07:26:39
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

agtc

ÖÁ×ðľ³æ (ÖøÃûдÊÖ)

¡ï
Àî½ðƽ(½ð±Ò+1):лл²ÎÓë
лл£¡³¤¼ûʶ¡£
ÂýÂýµÄ×ßÊÇΪÁË×ߵĸüÔ¶!
6Â¥2009-07-24 12:22:01
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

µç¹â×ÏÍâÏß

ľ³æ (ÖøÃûдÊÖ)

¡ï
Àî½ðƽ(½ð±Ò+1):лл²ÎÓë
³¤³¤¼ûʶ
whereamazinghappens!
7Â¥2009-07-24 12:39:16
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

alanpower

½ð³æ (СÓÐÃûÆø)


8Â¥2009-07-24 12:41:38
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

frank1577

Òø³æ (³õÈëÎÄ̳)

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
  ²»´í£¬Ñ§Ï°Ò»Ï¡£¡£
9Â¥2009-07-24 17:30:29
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

0523asia

ľ³æ (ÕýʽдÊÖ)

²»´íѧϰһÏÂ
10Â¥2009-07-24 22:39:20
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ Àî½ðƽ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á£¬Çóµ¼Ê¦ÊÕ +3 ÌìÌìºÃÔËÀ´Éϰ¶° 2026-03-24 3/150 2026-03-24 13:24 by allen-yin
[¿¼ÑÐ] 085404µç×ÓÐÅÏ¢284·ÖÇóµ÷¼Á +4 13659058978 2026-03-24 4/200 2026-03-24 12:15 by syl20081243
[¿¼ÑÐ] Çóµ÷¼Á +5 ÑÐÑУ¬½Óµç»° 2026-03-24 6/300 2026-03-24 11:39 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] 279·ÖÇóµ÷¼Á Ò»Ö¾Ô¸211 +18 chaojifeixia 2026-03-19 20/1000 2026-03-24 10:34 by dolphin_ycj
[¿¼ÑÐ] ×ÊÔ´Óë»·¾³ µ÷¼ÁÉêÇë(333·Ö) +6 holy J 2026-03-21 6/300 2026-03-24 09:51 by hengsmith
[¿¼ÑÐ] 291Çóµ÷¼Á +8 hhhhxn.. 2026-03-23 8/400 2026-03-23 23:15 by peike
[¿¼ÑÐ] 284Çóµ÷¼Á +3 yanzhixue111 2026-03-23 6/300 2026-03-23 22:58 by pswait
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖйúʯÓÍ´óѧ£¨»ª¶«£© ±¾¿ÆÆë³¹¤Òµ´óѧ +4 ʯÄÜΰ 2026-03-17 4/200 2026-03-23 17:51 by 17862566385
[¿¼ÑÐ] Ò»Ö¾Ô¸ÄϾ©Àí¹¤´óѧ085701×ÊÔ´Óë»·¾³302·ÖÇóµ÷¼Á +5 ¿ûè÷ÎÀ¶Ó 2026-03-18 7/350 2026-03-23 16:26 by lingjue
[¿¼ÑÐ] 276Çóµ÷¼Á +3 YNRYG 2026-03-21 4/200 2026-03-23 08:31 by ×íÔÚ·çÀï
[¿¼ÑÐ] Ò»Ö¾Ô¸Î÷°²½»Í¨´óѧ²ÄÁϹ¤³Ìרҵ 282·ÖÇóµ÷¼Á +11 ·ãÇÅZL 2026-03-18 13/650 2026-03-22 20:26 by edmund7
[¿¼ÑÐ] Çóµ÷¼ÁԺУÐÅÏ¢ +6 CX 330 2026-03-21 6/300 2026-03-22 15:25 by ÎÞи¿É»÷111
[¿¼²©] ÕÐÊÕ²©Ê¿1-2ÈË +3 QGZDSYS 2026-03-18 4/200 2026-03-22 10:25 by QGZDSYS
[¿¼ÑÐ] 265Çóµ÷¼Á +12 ÁºÁºÐ£Ð£ 2026-03-19 14/700 2026-03-21 13:38 by lature00
[¿¼ÑÐ] ²ÄÁÏѧѧ˶080502 337Çóµ÷¼Á-Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ +4 ˳˳˳mr 2026-03-18 5/250 2026-03-21 10:22 by luoyongfeng
[¿¼ÑÐ] Ò»Ö¾Ô¸ÎäÀí²ÄÁÏ305·ÖÇóµ÷¼Á +6 ÏëÉϰ¶µÄÀðÓã 2026-03-18 7/350 2026-03-21 01:03 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖØÇì´óѧ085700×ÊÔ´Óë»·¾³×¨Ë¶£¬×Ü·Ö308Çóµ÷¼Á +3 īīĮ 2026-03-18 3/150 2026-03-21 00:39 by JourneyLucky
[¿¼ÑÐ] Çóµ÷¼Á£¬Ò»Ö¾Ô¸:ÄϾ©º½¿Õº½Ìì´óѧ´óѧ £¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶£¬×Ü·Ö289·Ö +4 @taotao 2026-03-19 4/200 2026-03-20 22:14 by JourneyLucky
[¿¼ÑÐ] ²ÄÁÏѧ˶318Çóµ÷¼Á +5 February_Feb 2026-03-19 5/250 2026-03-19 23:51 by 23Postgrad
[¿¼ÑÐ] ²ÄÁϹ¤³Ìר˶µ÷¼Á +5 204818@lcx 2026-03-17 6/300 2026-03-18 22:55 by 204818@lcx
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û